%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
104 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-02T15:47:25Z
2024-03-19T00:14:26-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-19T00:14:26-07:00
application/pdf
Heather
2004-420.mar
uuid:7fa63cea-1dd2-11b2-0a00-9309271d5700
uuid:7fa63cec-1dd2-11b2-0a00-bf0000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
122 0 obj
[126 0 R]
endobj
123 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 59.968 737.5293 Tm
[(6.)-875.1 (T)69.9 (orre )54.8 (Alonso JC, Rodriguez Perez )54.8 (A, )54.8 (Arribas Castrillo JM, Ballina)]TJ
1.675 -1.25 Td
(Garcia L, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis)Tj
0 -1.25 TD
[(\(P)91.7 (A\): a clinical, immunological and radiological study of 180)]TJ
T*
(patients. Br J Rheumatol 1991;30:245-50.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (V)110.8 (eale D, Rogers S, FitzGerald O. Classification of clinical subset in)]TJ
1.675 -1.25 Td
(psoriatic arthritis. Br J Rheumatol 1994;33:133-8.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (McGonagle D, Conaghan PG, Emery P)110.7 (. Psoriatic arthritis, a unified)]TJ
1.675 -1.25 Td
[(concept twenty years on. )54.8 (Arthritis Rheum 1999;42:1080-6.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Fourni\216 B, Crognier L, )54.8 (Arnaud C, et al. Proposition de crit\217res de)]TJ
1.675 -1.25 Td
(classification du rhumatisme psoriasique, Etude pr\216liminaire de 260)Tj
T*
(patients. Rev Rhum 1999;66:513-24.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (McGonagle D, Gibbon )17.7 (W)91.8 (, Emery P)110.7 (. Classification of inflammatory)]TJ
2.175 -1.25 Td
[(arthritis by enthesitis. Lancet 1998;352:1)36.8 (137-40.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Dougados M, van der Linden S, Juhlin R, et al and )17.7 (The European)]TJ
2.1381 -1.25 Td
[(Spondylarthropathy Study Group. )17.7 (The European)]TJ
T*
(Spondylarthropathy Study Group preliminary criteria for the )Tj
T*
[(classification of spondylarthropathy)64.9 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:1218-27.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Amor B, Dougados M, Mijiawa M. Criteria of the classification of)]TJ
2.175 -1.25 Td
(spondylarthopathies [French]. Rev Rhum Mal Osteoartic)Tj
0 Tc 0 Tw T*
(1990;57:85-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Helliwell P)110.7 (, Marchesoni )54.8 (A, Peters M, Barker M, and )17.7 (W)39.8 (right )17.7 (V)128.9 (.)-0.1 ( )54.8 (A)-220.1 (re-)]TJ
2.175 -1.25 Td
(evaluation of the osteoarticular manifestations of psoriasis. Br )Tj
T*
(J Rheumatol 1991;30:339-45.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Scarpa R, Oriente P)110.7 (,)-0.1 ( Pucino )54.8 (A, et al. Psoriatic arthritis in psoriatic)]TJ
2.175 -1.25 Td
(patients. Br J Rheumatol 1984;23:246-50.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Gladmann D, Shuckett R, Russell ML, )17.7 (Thorne JC, Schachter RK.)]TJ
2.175 -1.25 Td
(Psoriatic arthritis: clinical and laboratory analysis of 220 patients. Q\
)Tj
0 Tc T*
(J Med 1987;62:127-41.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral)]TJ
2.175 -1.25 Td
[(joint disease in psoriatic arthritis: a 5-yr prospective study)64.8 (.)]TJ
T*
(Rheumatology Oxford 2003;42:778-83.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Palazzi C, Olivieri I, Petricca )54.8 (A, Salvarani C. Rheumatoid arthritis)]TJ
2.175 -1.25 Td
[(or psoriatic symmetric polyarthritis? )54.8 (A)-220.1 (dif)17.7 (ficult dif)17.7 (ferential )]TJ
T*
(diagnosis. Clin Exp Rheumatol 2002;20:3-4.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Leone N, Pellicano R, )54.8 (Ariata-Maiocco I, et al. Mixed )]TJ
2.175 -1.25 Td
(cryoglobulinemia and chronic hepatitis C infection: the rheumatic)Tj
T*
[(manifestations. J Med )17.7 (V)59.8 (irol 2002;66:200-3.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (V)110.8 (an Schaardenbur)17.7 (g D, Lagaay )54.8 (AM, Otten HG, Breedveld FC. )17.7 (The)]TJ
2.175 -1.25 Td
(relation between class-specific serum rheumatoid factors and age in)Tj
T*
(the general population. Br J Rheumatol 1993;32:546-9.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Cimmino MA, Salvarani C, Macchioni P)110.7 (, et al. Extra-articular )]TJ
2.175 -1.25 Td
(manifestations in 587 Italian patients with rheumatoid arthritis.)Tj
T*
(Rheumatol Int 2000;19:213-7.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Sebbag M, Simon M, )17.7 (V)59.8 (incent C, et al. )17.7 (The antiperinuclear factor)]TJ
2.175 -1.25 Td
(and the so-called antikeratin antibodies are the same )Tj
T*
(rheumatoid-specific autoantibodies. J Clin Invest 1995;95:2672-9.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Y)99.8 (ouinou P)110.7 (, Mass\216 R, Peu-Duvallon P)110.7 (, et al. )54.8 (Antiperinuclear factors)]TJ
2.175 -1.25 Td
(in psoriasis. Correlation with other serological abnormalities in 90)Tj
T*
[(patients [French]. )54.8 (Ann Dermatol )17.7 (V)110.8 (enereol 1982;109:359-64.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Calzavara-Pinton PG, Franceschini F)79.7 (, Manera C, et al.)]TJ
2.175 -1.25 Td
[(Antiperinuclear factor in psoriatic arthropathy)64.8 (. J )54.8 (Am )54.8 (Acad Dermatol)]TJ
0 Tc 0 Tw T*
(1999;40:910-3.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Schellekens GA, de Jong BA)79.7 (W)91.8 (,)-0.1 ( van den Hoogen FHJ, van de Putte)]TJ
2.175 -1.25 Td
(LBA. Citrulline is an essential constituent of antigenic determinants)Tj
T*
(recognized by rheumatoid arthritis-specific autoantibodies. J Clin)Tj
T*
(Invest 1998;101:273-81.)Tj
30.8875 70 Td
[(25.)-875.1 (Schellekens GA, )17.7 (V)59.8 (isser H, de Jong BA)79.7 (W)91.8 (, et al. )17.7 (The diagnostic)]TJ
2.175 -1.25 Td
(properties of rheumatoid arthritis antibodies recognizing a cyclic)Tj
T*
[(citrullinated peptide. )54.8 (Arthritis Rheum 2000;43:155-63. )]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Bas S, Genevay S, Meyer O, Gabay C. )54.8 (Anti-cyclic citrullinated)]TJ
2.175 -1.25 Td
[(peptide antibodies, IgM and IgA)-220.2 (rheumatoid factors in the )]TJ
T*
(diagnosis and prognosis of rheumatoid arthritis. Rheumatology)Tj
0 Tc T*
(Oxford. 2003;42:677-80.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875.1 (Bizzaro N, Mazzanti G, )17.7 (T)69.9 (onutti E, )17.7 (V)59.8 (illalta D, )17.7 (T)69.9 (ozzoli R. Diagnostic)]TJ
2.175 -1.25 Td
(accuracy of the anti-citrulline antibody assay for rheumatoid arthri-)Tj
T*
(tis. Clin Chem 2001;47:1089-93.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Krott E, de Jong BA)79.7 (W)91.8 (, van Leeuwen MA, et al. )17.7 (The prognostic)]TJ
2.175 -1.25 Td
(value of anti-cyclic citrullinated peptide antibodies in patients with)Tj
T*
[(recent-onset rheumatoid arthritis. )54.8 (Arthritis Rheum 2000;43:1831-5. )]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Meyer O, Labarre C, Dougados M, et al. )54.8 (Anti-citrullinated)]TJ
2.175 -1.25 Td
(protein/peptide antibody assays in early rheumatoid arthritis for)Tj
T*
[(predicting five years radiographic damage. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2003;62:120-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Salvarani C, Cantini F)79.7 (, Olivieri I, et al. Isolated peripheral enthesitis)]TJ
2.175 -1.25 Td
(and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
[(1997;24:1)36.9 (106-10.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Scarpa R, Cosentini E, Manguso F)79.7 (, et al. Clinical and genetic)]TJ
2.175 -1.25 Td
(aspects of psoriatic arthritis sine psoriasis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:2638-40.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Helliwell PS, Hetthen J, Sokoll K, et al. Joint symmetry in early)]TJ
2.175 -1.25 Td
(and late rheumatoid and psoriatic arthritis: comparison with a )Tj
T*
[(mathematical model. )54.8 (Arthritis Rheum 2000;43:865-71.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American College )]TJ
2.175 -1.25 Td
(preliminary core set of disease activity measures for rheumatoid)Tj
T*
[(arthritis clinical trials. )54.8 (Arthritis Rheum 1993;36:729-40.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (V)110.8 (an der heijde DMFM, van Riel PLCM, van Leuween MA, van\325)17.7 (t)]TJ
2.175 -1.25 Td
(Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors)Tj
T*
(for radiographic damage and physical disability in early rheumatoid)Tj
T*
(arthritis: a prospective follow-up study of 147 patients. Br )Tj
T*
(J Rheumatol 1992;31:519-25. )Tj
-2.175 -1.25 Td
[(35.)-875.1 (V)59.8 (isser H, le Cessie S, )17.7 (V)128.9 (os K, Breeveld FC, Hazes JMW)91.7 (. How to)]TJ
2.175 -1.25 Td
[(diagnose rheumatoid arthritis early)64.8 (. )54.8 (A)-220.1 (prediction model for )]TJ
T*
[(persistent \(erosive\) arthritis. )54.8 (Arthritis Rheum 2002;46:357-65.)]TJ
-2.175 -1.25 Td
[(36.)-875.1 (Pipitone N, Kingsley GH, Manzo )54.8 (A, Scott DL, Pitzalis C. Current)]TJ
2.175 -1.25 Td
(concept and new developments in the treatment of psoriatic )Tj
T*
[(arthritis. Rheumatology 2003;42:1)36.8 (138-48.)]TJ
-2.175 -1.25 Td
[(37.)-875.1 (Alberti )54.8 (A, Noventa F)79.7 (, Benvegn\235 L, Boccato S, Gatta )54.8 (A. Prevalence)]TJ
2.175 -1.25 Td
(of liver disease in a population of asymptomatic persons with )Tj
T*
[(hepatitis C virus infection. )54.8 (Ann Intern Med 2002;137:961-4.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F)79.7 (, Maio )17.7 (T)74 (,)]TJ
2.175 -1.25 Td
(Cimmino MA. Presenting features of polymyalgia rheumatica)Tj
T*
(\(PMR\) and rheumatoid arthritis with PMR like onset: a prospective)Tj
0 Tc T*
[(study)65 (. )54.9 (Ann Rheum Dis 2001;60:1021-4.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(39.)-875.1 (Kessel )54.8 (A, Rosner I, Zuckerman E, Golan )17.7 (TD, )17.7 (T)69.9 (oubi E. Use of)]TJ
2.175 -1.25 Td
(antikeratin antibodies to distinguish between rheumatoid arthritis)Tj
T*
(and polyarthritis associated with hepatitis C infection. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:610-2.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Bombardieri M, )54.8 (Alessandri C, Labbadia G, et al. Role of anti-cyclic)]TJ
2.175 -1.25 Td
(citrullinated peptide antibodies in discriminating patients with)Tj
T*
(rheumatoid arthritis from patients with chronic hepatitis C )Tj
T*
[(infection-associated polyarticular involvement. )54.8 (Arthritis Res )17.7 (Ther)]TJ
0 Tc 0 Tw T*
(2004;6:137-41.)Tj
ET
0 0 0 1 K
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 544.968 56.9344 Tm
(515)Tj
ET
0 0 0 0 k
53.03 71 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 58.0696 Tm
[(Bogliolo, et al: PsA)-257.3 (and anti-CCP)-257.3 (antibodies)]TJ
ET
0 0 0 0 k
/GS0 gs
103.13 82.08 407.5 -10.83 re
f*
0.5 w
103.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 19, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\6>B8aX%)`#sW9^gi70&RN6quZg[-#ZDcC3kt,!`V\fcN!)ro*bCm;h">/jFM=
*4MTin`+dk76;Rj]GEeZ#0YXdq>\dW\q`cZ;CHe#XRpUEs/7[s!C5^L;-U7&Lt'%E
9.??]NWIG1ZF6hD]F`@JTd#H\:59)_n0u.oECWKXV:C).GamMt_YRg990]aHE(GH&
A&J\t<'Fs/A,3:m^]Q@bLZO8G)[-D7s_0(VC8B/Y0@!F?
Cab[mKW>u8'j?!b\&uib"*40A)W\J]af3"QJT-R3S32ol/cP2C4`)*KibIK7NKkhi;$KScT[VUA+m!FIc/HFchM=!X?1uGks
a#Op>6m+U.5;&:0PU%R5\;-kFOdZc+3W$%bda_;V2-&-jRgB_BeTfd1MqZ,Y5)9eq
UYVqdlIGTP?(:"FL^ul/-0u>$Z8K<7Vaq?Y,TO><)QC)bOujKG)N`@!:$fQ,%OYRK'(9SHB6L?+2_k=a"N
.N5h:\(JN#Ufe5/b8c\>HDd\,]n',h,rL?`23jS89dd@-VO\WMb&=P#dj_`I8I)5g
O7AWI\[86MO@,9/!R-g-D5Q\8;ZqGb@^4EL!cH2>^;u*K+B<,`ei'jjqPP^i:/E')
9I6,L6p+JHH;"MkGJ*\$C0fY0+i0R)al(c2Und*G9Yc6:3;"`C02p"ON2s;eb4f
c+"^,9dfX)6:,s(Xd<=:fs]iG>=Nm!rE48_(\lV/IW<-kkH]SH?NU;89)(.~>
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
61 0 obj
<>
endobj
56 0 obj
<>
endobj
93 0 obj
<>
endobj
109 0 obj
<>
endobj
55 0 obj
<>
endobj
86 0 obj
<>stream
Ht{PYƻ ݉A6JӭX3uUP A#@+G <|(VGX5>vUwuu;jcjnթ[0'_vN:M\WFϗT7^!'+mtYO[^L(lS=^s~S0%ug
ZaЪwsѸ(ILWq
:*Mǭ$k3ҵJ*qDžrQ7(NNsjZe*MMғjMސB9&ZN-uDRV~c n7M0ǦX},JlaCXaa*ssOn+LnEUW0R.#
yqqx|g̈́e^%^pknbjA
O8|'
ѐ
ߒS"lZ 3dRDx+D-=ƮGҴUG"A.B3ۯPh0FC Q>Dɀh1GM}3%E!?zEu@{bgqѠ I83cFl9*}l)2E
WaR_>']МԑTxDR`pnPi@H! ~,E Mz[]#̃I aexj;GfХԠk<(&Nve@KVZ]"?;T'p ]R#Ӟ٢If
fWch -iZ]rbg0(|yH9G s\s8I=o~4u q˔̮k,Xm27- c7ۅ{r=_S/$'Mn2qwhjnmgQ?fPOL@sߣ DoEEquv RksB ~v#^(_p'I."[UžFXo;WhU1:
h2Qi* F| !*
!F+vm3:e|(`Qf"
So7amJ15 @yk5Ik*++27"Ϻ¯ч.AH݀zp\EQҶyW|V4MA
k70UW{;QΩbo8˿=w>hUt7l%"KiF
Cha3L7{&G߂bW
H6XgěcZcNw#Fy
(Wj-}nc y͌LF_۱g}쨭pj:FK=j^HGѮRVx.y9Zr]|>5~FZC60;mh5),!`/*]lJ--FM0
ՕHʞmfˉ,8#R,FRYKyPVfaX_cv8JeIÊ#*,e;q[Cm~
-~(wU?N6*Lcx
NY#n RP32^ S)'13S%h328R~l/h_:!٪wB0w)0!,|666MR9;q3':mUP-W5]QMWXėF7q{ut\Tg:jթZk8"Ȧ (4e ! MYB B E@*.U9(踌s9w߽붲qrKӠM 25jɏglaR?flېY,hfJ)(л8LOL$yuADeԤ%D>xGW~Dz{.dOLӯ1ie7[")p{bz9eۦ0`2IRk35 )BT\)$2ĺ56LVA;6;T$Pm 0VjiQ;'k`8=Yˇuh)ڂ(U @{(wagmxhEzXPKM-cF>
_yHX89`v>+oot6nY^BT>45$>[4ZC4~ivGc65O)GQT,2_j7%0s).Uxn}y+RN{!BY#"
̭
Â>Xka#qfmC( vkiyapo,> 7z;v;ᯮfkwhhY:Ud=D#QCu//v1mU+|ѥ9KQЇ4
}1S+lmh3rTa
JLu:@ɚCҸ\%L.eBHD-v+.ɼS4Ao]>KVlbchH_
I!cBk:c5XOX+:`[_>xоjf5^hmVGݫ}4 *>dWuieمTN%:rHyu.Fcj4N(lG,Pҹy"ה\kw8"p4#x5j/;@>@*j5Sh% h]mr:Q7Y@H+Ԫऌ "o'x{w~b QG4See${Zh;"M+yRoh[L|;]&"{
6pQ2gS/OV$x]21C/tȸtT*ͥ4.VsƊp+ 9]j9ހ9-9
"KCyq[yէ`=,m+g
:FI]/f ڷ{!p;b%
2_e1()aH8ߢ)a7:woF~qjdΤt4!VV59ǾNw̼yaNEXb.#//F5n.z?)U,GGy0^[3l#ekjIyoJuIm$zI⩡Gat[oAV#9:uzbi~)Z8paFSB:(-(Q`rtީuxgV&>#iƴiaԫRLga{fs)0xoN
7V2ev._Bn4,̈́^;'IRWXʙc[cQȂ8~X=O,,q6e)8){#ytvH~ohϞH)^t)Ϸz12B"l7 ){
+&C`oDުd8,}hi!.o#"0"\OMRVpm2v|ZȩhH$o};ro&?= s#!>zz^g\X?uB'|zۯA?п?\Kcުo:>Ys
ḠvB#:T_T[%0%Q_̮GYW.dK'8U}
-<(X"3rx}PJ+%$uZA/;K~HbuYuߝ3GL8EMBg4̋ooorMSDaVNVk:a75Z[tYS
d=t*(tX6!=Df|<;\+k|c@`:*MEs$\x^Hi/,_n뺶I;O{sã:AϦM;qlARxY2Uᅂ8XF;-W(5̓]
\`la7`]ڴhUguFvrBkJ}[U$Ҥh[jyN4":9eǛmEZDj4>RhtʮёN2t
hC+Q
D%~j{On:_;:l^i7QfVL:DHժ9ڝ;0*@((7+w1:Aj}5tuY,_UkQp5DwFYH&uPEFr*t5r63/3
.<Sc(YW(X)DQ>"RBkV3R z^mm /XALnlqCM'U-1GLvxJx, ;
endstream
endobj
62 0 obj
<>
endobj
85 0 obj
<>stream
H|T
PSW~///A(y<y/j[Q!)vAJ'` A4""?BDqVZV,ݵȎNGqK/nНiwٹsϽs~g9 "à<"RUyթʴ R^q]&9~oZN3v'ZZ&%$fߏ@{vk=a8uJP!ijFUf劔:zNۼS'JyVJUjФ4uFF%Wɕiqj<Ɇ%%)I*|}cn[\. [a05100.=°61#+ 5'RNP$h K&!ɓ"G:YtK\,jW+&9D:|cddhʪ)S^L
ziSSt"%SEuY3
Jnrpr;x0̈Gvsӯ+I,2}D.5F3Դ9Mf_A;ԅ|/<#408v9a -^kYWD<'JZ&ې}ؔQ5m!9=lK{kk;e=-U@vlM˨=ks۟UAB_dJt| #00pqTU0s̃pS6yWtlǞʲ
l_EY +%'Ygݏ.'Ķr5{6mJWp#_0P5
<" <<